TCRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
TScan Therapeutics Inc (TCRX) is not a strong buy at this moment for a beginner investor with a long-term focus. The technical indicators are bearish, there are no significant positive catalysts or trading signals, and the financial performance shows declining net income and EPS despite revenue growth. While hedge funds are buying, the lack of recent news, weak technicals, and no AI or SwingMax signals suggest holding off for now.
The technical indicators for TCRX are bearish. The MACD is below 0 and negatively contracting, the RSI is neutral at 35.97, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot level of 1.07, with key support at 1.009 and resistance at 1.131.
Hedge funds are significantly increasing their buying activity, with a 12447.81% increase over the last quarter. Analysts have raised the price target to $5 from $4 and maintain an Outperform rating. Revenue growth of 286.02% YoY in Q4 2025 is also a positive sign.
No recent news or significant insider trading trends. The stock's technical indicators are bearish, and there are no AI Stock Picker or SwingMax signals. Financial performance shows a significant drop in net income (-35.83% YoY) and EPS (-40.00% YoY).
In Q4 2025, TScan Therapeutics reported a 286.02% YoY increase in revenue to $2,567,000. However, net income dropped by -35.83% YoY to -$22,977,000, and EPS declined by -40.00% YoY to -0.18. Gross margin remained stable at 100%.
Wedbush raised the price target for TCRX to $5 from $4 and maintained an Outperform rating. The firm highlighted upcoming trial results and updates in 2026 as potential catalysts for the stock.
